Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.6462 | 0.6462 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.2326 | 0.2326 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.6462 | 0.6462 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.6462 | 0.6462 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.2326 | 0.2326 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.6462 | 0.6462 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 33.4 uM | PubChem BioAssay. Dose-response confirmation of uHTS inhibitor hits of Sentrin-Specific Protease 8 using a kinetic assay with Nedd8 Protein Substrate. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | 100 uM | PubChem BioAssay. Dose response confirmation of uHTS inhibitor hits of Sentrin-Specific Protease 8 using Nedd8 Protein Substrate. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.5623 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.